Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00424710
Status:
COMPLETED
Last Update Posted:
2014-11-05
First Post:
2007-01-18
Brief Title:
Ranibizumab for Polypoidal Choroidal Vasculopathy PCV
Sponsor:
Hawaii Pacific Health
Organization:
Hawaii Pacific Health
Study Overview
Official Title:
Phase I Study of Ranibizumab Injection for Polypoidal Choroidal Vasculopathy PEARL
Status:
COMPLETED
Status Verified Date:
2014-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PEARL
Brief Summary:
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceinsindocyanine green FAICG angiography
Detailed Description:
Previous treatment in subjects is allowed as long as appropriate washout period has elapsed Patients will be followed by 4M ETDRS vision testing as well as scheduled OCT ICG FA and Fundus Photography
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None